Sentry LLC Sells 21 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Sentry LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 944 shares of the medical research company’s stock after selling 21 shares during the period. Sentry LLC’s holdings in Thermo Fisher Scientific were worth $491,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Busey Bank grew its position in shares of Thermo Fisher Scientific by 3.6% in the 4th quarter. Busey Bank now owns 30,231 shares of the medical research company’s stock valued at $15,727,000 after purchasing an additional 1,044 shares during the period. Synergy Asset Management LLC acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at approximately $70,000. Strategic Planning Group LLC raised its holdings in shares of Thermo Fisher Scientific by 4.5% during the fourth quarter. Strategic Planning Group LLC now owns 6,615 shares of the medical research company’s stock worth $3,441,000 after acquiring an additional 286 shares during the period. Highland Capital Management LLC boosted its stake in Thermo Fisher Scientific by 10.0% in the 4th quarter. Highland Capital Management LLC now owns 33,979 shares of the medical research company’s stock worth $17,677,000 after purchasing an additional 3,102 shares during the period. Finally, Summa Corp. increased its holdings in Thermo Fisher Scientific by 7.4% during the 4th quarter. Summa Corp. now owns 1,456 shares of the medical research company’s stock worth $757,000 after purchasing an additional 100 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Morgan Stanley decreased their price objective on Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating for the company in a report on Monday, January 13th. Wells Fargo & Company reduced their target price on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Scotiabank initiated coverage on shares of Thermo Fisher Scientific in a research note on Monday, December 23rd. They issued a “sector perform” rating and a $605.00 price target on the stock. Redburn Atlantic began coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They issued a “buy” rating and a $680.00 price objective for the company. Finally, Bank of America lowered their price target on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research report on Friday, December 13th. Four research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $648.95.

Thermo Fisher Scientific Stock Down 2.9 %

TMO stock opened at $567.09 on Thursday. The business’s fifty day moving average price is $536.74 and its two-hundred day moving average price is $570.35. The stock has a market capitalization of $216.91 billion, a price-to-earnings ratio of 35.55, a PEG ratio of 3.82 and a beta of 0.76. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.48% and a return on equity of 17.49%. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.69 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio is 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock buyback program on Friday, November 15th that allows the company to buyback $4.00 billion in shares. This buyback authorization allows the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $558.12, for a total value of $5,581,200.00. Following the transaction, the chief executive officer now owns 33,608 shares in the company, valued at approximately $18,757,296.96. This trade represents a 22.93 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 34,850 shares of company stock valued at $19,123,197 in the last ninety days. 0.34% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.